web analytics

Immunovia and world-class teaching hospital finalize agreement for collection of pancreatic cancer blood samples for IMMray™ PanCan-d

LUND, SWEDEN― Immunovia AB (publ) (“Immunovia”) today announced that Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, USA, will participate in the validation of IMMray™ PanCan-d as part of the final steps to commercialization for the blood-based test for early diagnosis of pancreatic cancer. As previously communicated, (link to PR June 3, 2019 (https://immunovia.com/investors/press-releases/?id=4915)) the final three steps towards commercialization remain the same and are as follows: 1) commercial test model; 2) verification; 3) and validation of the commercial

Source: Immunovia and world-class teaching hospital finalize agreement for collection of pancreatic cancer blood samples for IMMray™ PanCan-d

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.